Valuation
- Market cap
- 2,028,302,000
- Revenue TTM
- $0
- Net income TTM
- $-198,790,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 591,300
- Avg volume
- 796,750
- Day's range
- $30.69 – $31.55
- Shares out
- 65,408,000
- Stochastic %K
- 9%
- Beta
- -2.46
- Analysts
- Strong Sell
- Price target
- $59.85
Company profile
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema du...
Show more
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 31 712036410
- Website
- https://pharvaris.com
- Address
- Grafenauweg 8, Zug, Switzerland
Latest news
No headlines yet.
